Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review

22Citations
Citations of this article
39Readers
Mendeley users who have this article in their library.

Abstract

Infliximab and adalimumab are monoclonal antibodies against tumor necrosis factor (anti-TNF) used to manage inflammatory bowel disease (IBD). Therapeutic Drug Monitoring (TDM) has been proven to prevent immunogenicity, to achieve better long-term clinical results and to save costs in IBD treatment. The aim of this study was to conduct a systematic review on cost-effectiveness analyses of studies that apply TDM of anti-TNF in IBD and to provide a critical analysis of the best scientific knowledge available in the literature. The quality of the included studies was assessed using Consolidated Health Economic Evaluation Reporting Standards (CHEERS). Cost-effectiveness of the TDM strategies was presented as total costs, cost savings, quality-adjusted life-years (QALY) and incremental cost-effectiveness ratio (ICER). Thirteen studies that examined the health economics of TDM of anti-TNF in IBD from 2013 to 2021 were included. Eight of them (61.5%) achieved a score between 17 and 23 on the CHEERS checklist. The comparison between the TDM strategy and an empirical strategy was cost saving. The ICER between reactive TDM and an empirical strategy was dominated (favorable) by reactive TDM, whereas the ICER value for proactive TDM compared to an empirical strategy ranged from EUR 56,845 to 3,901,554. This systematic review demonstrated that a TDM strategy is cost-effective or cost-saving in IBD.

References Powered by Scopus

The PRISMA 2020 statement: An updated guideline for reporting systematic reviews

48876Citations
N/AReaders
Get full text

Scoping studies: Towards a methodological framework

21699Citations
N/AReaders
Get full text

PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation

20825Citations
N/AReaders
Get full text

Cited by Powered by Scopus

ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment

58Citations
N/AReaders
Get full text

Reversing the Inflammatory Process—25 Years of Tumor Necrosis Factor-α Inhibitors

14Citations
N/AReaders
Get full text

Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases

12Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Marquez-Megias, S., Nalda-Molina, R., Sanz-Valero, J., Más-Serrano, P., Diaz-Gonzalez, M., Candela-Boix, M. R., & Ramon-Lopez, A. (2022, May 1). Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review. Pharmaceutics. MDPI. https://doi.org/10.3390/pharmaceutics14051009

Readers over time

‘22‘23‘24‘250481216

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 14

88%

Professor / Associate Prof. 1

6%

Researcher 1

6%

Readers' Discipline

Tooltip

Medicine and Dentistry 9

53%

Pharmacology, Toxicology and Pharmaceut... 5

29%

Nursing and Health Professions 2

12%

Chemistry 1

6%

Save time finding and organizing research with Mendeley

Sign up for free
0